Shantha Biotechnics wins UN contracts for combination vaccine

Published: 3-Sep-2009

Shantha Biotechnics has been awarded contracts by a United Nations agency for the supply of pentavalent vaccine SHAN5 - a combination vaccine of Diphtheria, Pertussis, Tetanus, Haemophilus influenza B, and Hepatitis B. The contracts, worth $340m (e237m), cover the period 2010-2012.


Shantha Biotechnics has been awarded contracts by a United Nations agency for the supply of pentavalent vaccine SHAN5 - a combination vaccine of Diphtheria, Pertussis, Tetanus, Haemophilus influenza B, and Hepatitis B. The contracts, worth $340m (e237m), cover the period 2010-2012.

Shantha is based in Hyderabad, India and develops, manufactures and markets several vaccines. Sanofi Pasteur took control of Shantha on August 31, 2009 through the acquisition of Merieux Alliance's French subsidiary ShanH, which owns a majority stake in Shantha.

In 1997, Shantha launched SHANVAC-B, the first recombinant Hepatitis B vaccine produced in India. SHANVAC-B, SHANTETRA (combination vaccine of Diphtheria, Pertussis, Tetanus, and Hepatitis B), SHAN5 and SHANTT (Tetanus toxoid vaccine) are prequalified by WHO for supplying to UN agencies globally.

You may also like